GSK says key trial data shows its RSV vaccine is ‘truly exceptional’

LONDON (Reuters) -Late-stage data unveiled on Thursday showed GSK’s respiratory syncytial virus (RSV) vaccine was 82.6% effective in a keenly watched late-stage study involving older adults.

RSV is a leading cause of pneumonia in toddlers and the elderly, causing thousands of hospitalisations and deaths each year, but the complex molecular structure of the virus and safety concerns have stymied efforts to develop a vaccine since it was first discovered in 1956.

The trial, which involved roughly 25,000 adults aged 60 and over, tested a single dose of the experimental vaccine against a placebo.

Vaccine efficacy against severe lower respiratory tract disease (LRTD) associated with an RSV infection was 94.1%, the British drugmaker said.

“These are truly exceptional results given that today RSV remains one of the major infectious diseases without a vaccine, despite over 60 years of research,” said Tony Wood, GSK Chief Scientific Officer, in a statement.

GSK is a key player in the race to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales for its maker.

The company said in June the trial had yielded statistically significant results for the shot, but on Thursday gave details about the performance of the vaccine.

(Reporting by Natalie Grover; Editing by Mark Potter and Jan Harvey)

*As an Amazon Associate I earn from qualifying purchases